Nobiletin is capable of regulating certain anti-cancer pathways in a colon cancer cell line

Basit Öğe Kaydı
dc.contributor.authorKisacam, Mehmet A. A.
dc.date.accessioned2024-09-18T20:25:09Z
dc.date.available2024-09-18T20:25:09Z
dc.date.issued2023
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractNatural remedies have the potential to improve conventional cancer therapies and enhance patient outcomes. Citrus polymethoxyflavone nobiletin has been demonstrated to have anticancer effects on several cancer cell lines. In this study, the anti-cancer activity of nobiletin is investigated on Bax, Bcl-2, HO-1, VEGF, MMP-7, Akt, p70S6K, 4EBP1, tuberin, and hamartin. IC50 doses were 403.6 mu M, 264 mu M, and 40 mu M, respectively, at 24, 48, and 72 h. Akt, Bax, Bcl-2, and p70S6K levels decreased at nobiletin concentrations greater than 100, 250, 500, and 1000 mu M, respectively. Nobiletin decreased HO-1 and VEGF levels at concentrations greater than 100 mu M. MMP-7 levels interestingly increased at 100 mu M but decreased at doses greater than 250 mu M. 4EBP1 levels increased, except from 2000 and 3000 mu M nobiletin concentrations. Tuberin levels increased at 10, 50, and 3000 mu M, decreased at 250 mu M, and remained unchanged at the rest of the concentrations. Nobiletin decreased hamartin levels; however, this decrease was statistically significant only at 10, 100, 250, 500, and 3000 mu M concentrations. Decreased Akt activity might be interpreted as nobiletin inhibiting mTORC1 activity and subsequently increased 4EBP1 and unchanged or decreased p70S6K protein levels. Akt activity can cause suppression of angiogenesis via decreased VEGF, MMP-7, and HO-1 levels at concentrations greater than 500 mu M. These results are significant as a nobiletin therapy could prevent colon cancer progression by inhibiting Akt signaling and angiogenesis.en_US
dc.identifier.doi10.1007/s00210-022-02354-9
dc.identifier.endpage555en_US
dc.identifier.issn0028-1298
dc.identifier.issn1432-1912
dc.identifier.issue3en_US
dc.identifier.pmid36454256en_US
dc.identifier.scopus2-s2.0-85143231485en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage547en_US
dc.identifier.urihttps://doi.org/10.1007/s00210-022-02354-9
dc.identifier.urihttps://hdl.handle.net/20.500.12483/10108
dc.identifier.volume396en_US
dc.identifier.wosWOS:000914905000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofNaunyn-Schmiedebergs Archives of Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFlavonoidsen_US
dc.subjectNobiletinen_US
dc.subjectColon canceren_US
dc.subjectAkten_US
dc.subjectAngiogenesisen_US
dc.titleNobiletin is capable of regulating certain anti-cancer pathways in a colon cancer cell lineen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
1.55 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu